Within the scope of each thematic topic, statements were developed by the panelists during the one-day meeting concerning how to interpret PSMA PET/CT to define response and progression in patients treated for metastatic PCa and when to use it. This evidence concerns the gene FOLH1 and posterior cortical atrophy.